Cell Therapy Technologies Market

Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single Use Equipment, Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Biopharma, CMOs), Region - Global Forecast to 2027

Report Code: BT 6823 Aug, 2022, by marketsandmarkets.com

[218 Pages Report] The cell therapy technologies market is projected to reach USD 8.0 billion by 2027 from USD 4.0 billion in 2022, at a CAGR of 14.6% during the forecast period. The rising government investments in cell-based research, increasing incidence of chronic and infectious diseases, large number of oncology-related cell therapy clinical trials, and increasing GMP certifications for cell therapy production facilities are the key factors driving the growth of this market.

Cell Therapy Technologies Market

To know about the assumptions considered for the study, Request for Free Sample Report

Global Cell Therapy Technologies Market Dynamics

Rising Incidence of Chronic Diseases

Cell therapy has a wide range of applications in providing diagnostic/prognostic information as well as during clinical research related to HIV/AIDS, cancer, and various infectious diseases. Several factors, such as the growth in the population, climate change, and increasing contact between humans and animals, have increased the threat of new virus outbreaks. This has led to increase in cell therapy treatments, thus fueling the market growth.

Dearth of skilled labor

Despite technological innovation and product development over the last decade, the market has been affected by the lack of a trained workforce to operate complex instruments. According to a research study carried out by the Gatsby Foundation, by 2030, the UK will require a further 700,000 technicians to support the economy. The shortage of skilled professionals is one of the key factors limiting the adoption and utilization of cell therapy technologies in several countries across the globe.

Emergence of iPSCs as alternatives to ESCs

iPSCs can be used for various applications, including the development of regenerative medicine and drug discovery (such as disease modeling and cytotoxicity studies), thus reducing the overall cost of clinical trials. The use of iPSCs for stem cell therapy allows for the generation of pluripotent cells that are identical to the patient’s genetic map. Due to such advantages, the use of iPSCs in cell therapy research is increasing.

Survival of small players and new entrants

Established players have a robust product portfolio and strong brand recognition. As a result, it is difficult for small players and new entrants to compete with established players. Also, as large investments are required for the R&D and launch of innovative products in the market, it is difficult for small players to sustain their operations and compete with established players that have large R&D budgets.

The media, sera, and reagents segment is expected to have the dominant share of the cell therapy technologies market  in 2021:

The media, sera, and reagents segment is expected to account for the largest share of the cell therapy technologies market and register the highest CAGR during the forecast period. The large share of this segment is attributed to the high demand for growth factors and media in cell-based experiments and cancer research and the growing number of product launches.

Cell Therapy Technologies Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for cell therapy technologies market in 2021.

The market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the cell therapy technologies market. The large share of this regional segment can be attributed to the high burden of chronic diseases coupled with increase in R&D in North America.

Key Market Players

Key players in the market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Becton, Dickinson and Company (US), Lonza Group (Switzerland), Sartorius AG (Germany), and Terumo BCT (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD)

Segments covered

Product, Process, Cell type, End User and Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

Companies covered

Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Becton, Dickinson and Company (US), Fresenius SE & Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), MaxCyte Inc. (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), TrakCel (UK), L7 Informatics, Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), GPI Iberia (Spain), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Manufacturing Corporation (US)

This report categorizes the cell therapy technologies market into the following segments and subsegments

By Product

  • Media, Sera, and Reagents
  • Cell Engineering Products
  • Cell Culture Vessels
  • Cell Therapy Equipment
  • Cell Processing Equipment
  • Single-use Equipment
  • Other Equipment
  • Systems and Software
  • Other Products

By Process

  • Cell Processing
  • Cell Preservation, Distribution, and Handling
  • Process Monitoring and Quality Control

By Cell Type

  • T-cells
  • Stem Cells
  • Other Cells

By End User

  • Biopharmaceutical and Biotechnology Companies
  • CROs and CMOs
  • Research Institutes and Cell Banks

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • RoE
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments

  • In January 2021, Thermo Fisher Scientific launched the first T-cell medium designed specifically for allogeneic cell therapy workflows.
  • In March 2020, Danaher acquired the Biopharma business from General Electric Company's Life Sciences division. The acquisition has led to the formation of a new business named Cytiva, a standalone operating company within Danaher's Life Sciences segment.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 31)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
                    FIGURE 1 CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH DATA
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 BREAKDOWN OF PRIMARIES BY RESPONDENT, DESIGNATION, AND REGION: CELL THERAPY TECHNOLOGIES MARKET
    2.2 MARKET ESTIMATION METHODOLOGY
          FIGURE 4 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2021
          FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTIONS
          FIGURE 7 CELL THERAPY TECHNOLOGIES MARKET (SUPPLY SIDE): CAGR PROJECTIONS
          FIGURE 8 CELL THERAPY TECHNOLOGIES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
    2.4 DATA TRIANGULATION
          FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS
    2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 45)
    FIGURE 10 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 GEOGRAPHICAL SNAPSHOT OF CELL THERAPY TECHNOLOGIES MARKET
   
4 PREMIUM INSIGHTS (Page No. - 49)
    4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW
          FIGURE 15 INCREASING GOVERNMENT INVESTMENTS IN CELL-BASED RESEARCH TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SHARE, BY CELL TYPE AND COUNTRY (2021)
          FIGURE 16 T CELLS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021
    4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2022 VS. 2027
          FIGURE 17 MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 2027
    4.4 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PROCESS, 2022
          FIGURE 18 CELL PROCESSING SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022
    4.5 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
          FIGURE 19 ASIA PACIFIC COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 52)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 20 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing government investments in cell-based research
                                TABLE 1 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2019 (USD MILLION)
                    5.2.1.2 Rising incidence of chronic and infectious diseases
                    5.2.1.3 Large number of oncology-related cell therapy clinical trials
                                FIGURE 21 CANCER CELL THERAPY PIPELINE (MARCH 2019–MARCH 2020)
                    5.2.1.4 Increasing GMP certifications for cell therapy production facilities
                                TABLE 2 EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of cell-based research and low success rate
                                TABLE 3 COST OF CELL THERAPY EQUIPMENT
                    5.2.2.2 Dearth of skilled professionals
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emergence of iPSCs as alternatives to ESCs
                    5.2.3.2 Increased focus on personalized medicine
                    5.2.3.3 Increasing public-private partnerships for development of cell therapies
                    5.2.3.4 Emerging Asian markets
           5.2.4 CHALLENGES
                    5.2.4.1 Survival of small players and new entrants
    5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
           FIGURE 22 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS
    5.4 INDICATIVE PRICING MODEL ANALYSIS
           TABLE 4 PRICING ANALYSIS OF CELL THERAPY PRODUCTS
    5.5 TECHNOLOGY ANALYSIS
    5.6 VALUE CHAIN ANALYSIS
           FIGURE 23 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE
    5.7 SUPPLY CHAIN ANALYSIS
           FIGURE 24 CELL THERAPY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS
    5.8 ECOSYSTEM ANALYSIS OF CELL THERAPY TECHNOLOGIES MARKET
          FIGURE 25 ECOSYSTEM ANALYSIS
          TABLE 5 SUPPLY CHAIN ECOSYSTEM
    5.9 KEY CONFERENCES AND EVENTS IN 2022–2023
          TABLE 6 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    5.10 REGULATORY ANALYSIS
           5.10.1 NORTH AMERICA
                     TABLE 7 NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES
           5.10.2 EUROPE
                     TABLE 8 EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES
           5.10.3 ASIA PACIFIC
                     TABLE 9 ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES
           5.10.4 REST OF THE WORLD
                     TABLE 10 REST OF THE WORLD: REGULATORY LANDSCAPE FOR CELL THERAPIES
    5.11 PORTER’S FIVE FORCES ANALYSIS
           TABLE 11 CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.11.1 THREAT OF NEW ENTRANTS
           5.11.2 THREAT OF SUBSTITUTES
           5.11.3 BARGAINING POWER OF SUPPLIERS
           5.11.4 BARGAINING POWER OF BUYERS
           5.11.5 DEGREE OF COMPETITION
    5.12 PATENT ANALYSIS
           FIGURE 26 PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JANUARY 2012–JULY 2022
           TABLE 12 INDICATIVE LIST OF PATENTS IN CELL THERAPY TECHNOLOGIES MARKET
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 27 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF CELL THERAPY PRODUCTS
           5.13.2 BUYING CRITERIA FOR CELL THERAPY PRODUCTS
                     FIGURE 28 KEY BUYING CRITERIA FOR END USERS

6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT (Page No. - 73)
    6.1 INTRODUCTION
          TABLE 13 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
    6.2 MEDIA, SERA, AND REAGENTS
           6.2.1 MEDIA, SERA, AND REAGENTS ARE INTEGRAL PARTS OF CELL PROCESSING
                    TABLE 14 CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 15 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 16 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 17 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR MEDIA, SERA, AND REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 CELL ENGINEERING PRODUCTS
           6.3.1 AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS SUPPORTS MARKET GROWTH
                    TABLE 18 CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 19 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 20 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 21 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ENGINEERING PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 CELL CULTURE VESSELS
           6.4.1 CELL CULTURE VESSELS ARE WIDELY USED FOR CELL GROWTH
                    TABLE 22 CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 23 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 24 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 25 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CULTURE VESSELS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.5 EQUIPMENT
          TABLE 26 CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)
          TABLE 27 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 28 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 29 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 30 CELL THERAPY TECHNOLOGIES MARKET FOR EQUIPMENT, BY TYPE, 2020–2027 (USD MILLION)
           6.5.1 CELL PROCESSING EQUIPMENT
                    6.5.1.1 Cell processing equipment segment dominates cell therapy equipment market
                                TABLE 31 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 32 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 33 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 34 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
           6.5.2 SINGLE-USE EQUIPMENT
                    6.5.2.1 Benefits of single-use equipment have ensured end-user demand
                                TABLE 35 CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 36 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 37 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 38 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR SINGLE-USE EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
           6.5.3 OTHER EQUIPMENT
                    TABLE 39 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 40 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 41 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 42 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
    6.6 SYSTEMS AND SOFTWARE
           6.6.1 SYSTEMS AND SOFTWARE ARE USED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING
                    TABLE 43 CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 44 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 45 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 46 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR SYSTEMS AND SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
    6.7 OTHER PRODUCTS
          TABLE 47 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 48 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 49 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 50 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)

7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS (Page No. - 90)
    7.1 INTRODUCTION
          TABLE 51 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
    7.2 CELL PROCESSING
           7.2.1 CELL PROCESSING MAKES WIDE USE OF CELL THERAPY INSTRUMENTS
                    TABLE 52 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 53 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 54 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 55 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 CELL PRESERVATION, DISTRIBUTION, AND HANDLING
           7.3.1 INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH
                    TABLE 56 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 57 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 58 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 59 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 PROCESS MONITORING AND QUALITY CONTROL
           7.4.1 PROCESS MONITORING IS ESSENTIAL TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING
                    TABLE 60 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 61 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 62 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 63 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2020–2027 (USD MILLION)

8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE (Page No. - 97)
    8.1 INTRODUCTION
          TABLE 64 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
    8.2 T CELLS
           8.2.1 RESEARCH CONDUCTED ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH
                    TABLE 65 CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 66 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 67 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 68 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 STEM CELLS
           8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE SEGMENT GROWTH
                    TABLE 69 CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 70 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 71 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 72 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 OTHER CELLS
          TABLE 73 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 74 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 75 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 76 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2020–2027 (USD MILLION)

9 CELL THERAPY TECHNOLOGIES MARKET, BY END USER (Page No. - 104)
    9.1 INTRODUCTION
          TABLE 77 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.2 BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
           9.2.1 RISING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE SEGMENT GROWTH
                    TABLE 78 CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 79 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 80 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 81 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.3 CROS AND CMOS
           9.3.1 RISING FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH
                    TABLE 82 CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 83 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 84 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 85 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS AND CMOS, BY COUNTRY, 2020–2027 (USD MILLION)
    9.4 RESEARCH INSTITUTES AND CELL BANKS
           9.4.1 MARKET GROWTH IS SUPPORTED BY RISING RESEARCH ACTIVITY
                    TABLE 86 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 87 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 88 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 89 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2020–2027 (USD MILLION)

10 CELL THERAPY TECHNOLOGIES MARKET, BY REGION (Page No. - 111)
     10.1 INTRODUCTION
             TABLE 90 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2020–2027 (USD MILLION)
     10.2 NORTH AMERICA
             FIGURE 29 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
             TABLE 91 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 92 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 93 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 94 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
             TABLE 95 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
             TABLE 96 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Increasing R&D activities to support market growth
                                      TABLE 97 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 98 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 99 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                                      TABLE 100 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                                      TABLE 101 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Increasing government funding to drive adoption of cell therapy instruments
                                      TABLE 102 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 103 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 104 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                                      TABLE 105 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                                      TABLE 106 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.3 EUROPE
             TABLE 107 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 108 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 109 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 110 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
             TABLE 111 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
             TABLE 112 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Germany holds largest share of European market
                                      TABLE 113 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 114 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 115 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                                      TABLE 116 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                                      TABLE 117 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Favorable funding and investment scenario to drive market growth
                                      TABLE 118 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 119 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 120 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                                      TABLE 121 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                                      TABLE 122 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Availability of government and private support to drive market growth
                                      TABLE 123 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 124 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 125 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                                      TABLE 126 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                                      TABLE 127 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Initiatives favoring cell and gene therapy development to support market growth
                                      TABLE 128 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 129 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 130 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                                      TABLE 131 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                                      TABLE 132 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Increasing funding from private and public organizations to aid market growth
                                      TABLE 133 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 134 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 135 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                                      TABLE 136 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                                      TABLE 137 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.6 REST OF EUROPE
                        TABLE 138 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 139 ROE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 140 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                        TABLE 141 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                        TABLE 142 ROE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.4 ASIA PACIFIC
             FIGURE 30 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
             TABLE 143 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 144 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 145 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 146 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
             TABLE 147 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
             TABLE 148 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 Increasing cell therapy-based trials to support market growth
                                      TABLE 149 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 150 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 151 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                                      TABLE 152 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                                      TABLE 153 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Rising geriatric population and growing disease prevalence to drive market growth
                                      TABLE 154 JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
                                      TABLE 155 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 156 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 157 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                                      TABLE 158 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                                      TABLE 159 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Favorable government regulations to support market growth
                                      TABLE 160 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 161 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 162 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                                      TABLE 163 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                                      TABLE 164 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC
                        TABLE 165 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 166 ROAPAC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 167 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                        TABLE 168 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                        TABLE 169 ROAPAC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.5 LATIN AMERICA
             10.5.1 AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET GROWTH
                        TABLE 170 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 171 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 172 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                        TABLE 173 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                        TABLE 174 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.6 MIDDLE EAST AND AFRICA
             10.6.1 INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET GROWTH
                        TABLE 175 MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 176 MIDDLE EAST AND AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 177 MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2020–2027 (USD MILLION)
                        TABLE 178 MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2020–2027 (USD MILLION)
                        TABLE 179 MIDDLE EAST AND AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 150)
     11.1 INTRODUCTION
     11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
             FIGURE 31 CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED
     11.3 MARKET SHARE ANALYSIS
             FIGURE 32 CELL THERAPY TECHNOLOGIES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2021)
             TABLE 180 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION
     11.4 REVENUE ANALYSIS
             FIGURE 33 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)
     11.5 COMPANY EVALUATION MATRIX
             FIGURE 34 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX, 2021
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
     11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES
             FIGURE 35 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
             11.6.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
                        TABLE 181 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY START-UPS/SMES
                        TABLE 182 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES
     11.7 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
             11.7.1 COMPANY FOOTPRINT (25 COMPANIES)
                        TABLE 183 COMPANY FOOTPRINT ANALYSIS: KEY PLAYERS
             11.7.2 PRODUCT FOOTPRINT (25 COMPANIES)
                        TABLE 184 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS
             11.7.3 PROCESS FOOTPRINT (25 COMPANIES)
                        TABLE 185 PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS
             11.7.4 REGIONAL FOOTPRINT (25 COMPANIES)
                        TABLE 186 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS
     11.8 COMPETITIVE SCENARIO AND TRENDS
             11.8.1 PRODUCT LAUNCHES
                        TABLE 187 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES (JANUARY 2019–JULY 2022)
             11.8.2 DEALS
                        TABLE 188 CELL THERAPY TECHNOLOGIES MARKET: DEALS (JANUARY 2019–JULY 2022)
             11.8.3 OTHER DEVELOPMENTS
                        TABLE 189 CELL THERAPY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS (JANUARY 2019–JULY 2022)

12 COMPANY PROFILES (Page No. - 165)
     12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, MnM view, Key strengths/right to win, Strategic choices made, Weaknesses and competitive threats)*
             12.1.1 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 190 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
             12.1.2 MERCK KGAA
                        TABLE 191 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT
             12.1.3 DANAHER CORPORATION
                        TABLE 192 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT
             12.1.4 LONZA GROUP
                        TABLE 193 LONZA GROUP: BUSINESS OVERVIEW
                        FIGURE 39 LONZA GROUP: COMPANY SNAPSHOT
             12.1.5 SARTORIUS AG
                        TABLE 194 SARTORIUS AG: BUSINESS OVERVIEW
                        FIGURE 40 SARTORIUS AG: COMPANY SNAPSHOT
             12.1.6 TERUMO BCT, INC.
                        TABLE 195 TERUMO CORPORATION: BUSINESS OVERVIEW
                        FIGURE 41 TERUMO CORPORATION: COMPANY SNAPSHOT
             12.1.7 BECTON, DICKINSON AND COMPANY
                        TABLE 196 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
             12.1.8 FRESENIUS SE & CO. KGAA
                        TABLE 197 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
                        FIGURE 43 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT
             12.1.9 AVANTOR, INC.
                        TABLE 198 AVANTOR, INC.: BUSINESS OVERVIEW
                        FIGURE 44 AVANTOR, INC.: COMPANY SNAPSHOT
             12.1.10 BIO-TECHNE CORPORATION
                        TABLE 199 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
                        FIGURE 45 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT
             12.1.11 CORNING INCORPORATED
                        TABLE 200 CORNING INCORPORATED: BUSINESS OVERVIEW
                        FIGURE 46 CORNING INCORPORATED: COMPANY SNAPSHOT
             12.1.12 FUJIFILM IRVINE SCIENTIFIC
                        TABLE 201 FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 47 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT
             12.1.13 MAXCYTE, INC.
                        TABLE 202 MAXCYTE: BUSINESS OVERVIEW
                        FIGURE 48 MAXCYTE: COMPANY SNAPSHOT
*Details on Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
     12.2 OTHER PLAYERS
             12.2.1 WERUM IT SOLUTIONS
             12.2.2 ROOSTERBIO, INC.
             12.2.3 SIRION BIOTECH GMBH
             12.2.4 TRAKCEL
             12.2.5 L7 INFORMATICS
             12.2.6 MILTENYI BIOTEC
             12.2.7 STEMCELL TECHNOLOGIES INC.
             12.2.8 GPI IBERIA (FORMERLY HEMASOFT)
             12.2.9 MAK-SYSTEM
             12.2.10 ORGANABIO, LLC
             12.2.11 IXCELLS BIOTECHNOLOGIES
             12.2.12 WILSON WOLF MANUFACTURING CORPORATION

13 APPENDIX (Page No. - 212)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 CUSTOMIZATION OPTIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the cell therapy technologies market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell therapy technologies market. The secondary sources used for this study include Annual Reports, SEC Filings, Investor Presentations, WHO, CDC, International Society for Stem Cell Research, International Society for Cellular Therapy (ISCT), American Society of Gene & Cell Therapy (ASGCT), International Cell Research Organization (ICRO), European Society of Gene and Cell Therapy (ESGCT), American Society for Cell Biology, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Cell Therapy Technologies Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell therapy technologies market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the cell therapy technologies business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global cell therapy technologies market based on the product, process, cell type, end user and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall cell therapy technologies market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the cell therapy technologies market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles
Report Code
BT 6823
Published ON
Aug, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cell Therapy Technologies Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback